Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
August 16, 2022 07:12 AM EDTUpdated 07:23 AM
Deals

Gilead doles out $280M up­front to re­gain Trodelvy rights in Chi­na, oth­er re­gion­al ter­ri­to­ries

Max Gelman

Senior Editor

A lit­tle over two months af­ter Trodelvy earned its first ap­proval in Chi­na, Gilead is mak­ing moves to re­gain the drug’s rights in the coun­try …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

A service from the Financial Times